CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发和/或难治性慢性淋巴细胞白血病的治疗
英文原题：Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia.
查看英文原题
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
共价布鲁顿酪氨酸激酶抑制剂（cBTKis），包括acalabrutinib和zanubrutinib，以及BCL2抑制剂venetoclax，目前在一线及复发和/或难治性（R/R）慢性淋巴细胞白血病（CLL）中均已纳入序贯治疗。一个较新的挑战是既往暴露于cBTKi和BCL2抑制剂后R/R CLL患者的管理。本文中，我们综述了既往接受过化学免疫治疗、cBTKi和venetoclax为基础的治疗后R/R CLL的管理。我们综述了“双重暴露”CLL的治疗选择，包括venetoclax再治疗、pirtobrutinib以及lisocabtagene maraleucel CAR-T 细胞治疗。新兴治疗选择包括临床试验中的药物，如BTK降解剂和双特异性抗体。
展开英文摘要原文
Covalent Bruton's tyrosine kinase inhibitors (cBTKis), including acalabrutinib and zanubrutinib, and the BCL2 inhibitor venetoclax are currently sequenced in both front-line and relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL). A newer challenge is the management of patients with R/R CLL after exposure to both a cBTKi and BCL2 inhibitor.
Herein, we review the management of R/R CLL following prior treatment with chemoimmunotherapy, cBTKi, and venetoclax-based therapy.
We review treatment options for "double exposed" CLL including venetoclax retreatment, pirtobrutinib, and CAR T-cell therapy with lisocabtagene maraleucel. Emerging treatment options include agents in clinical trials such as BTK degraders and bispecific antibodies.
论文信息
- 作者
- Kagerer A、Thompson MC
- 第一作者单位
- Department of Medicine, New York Presbyterian/Weill Cornell Medical College, 530 E 74th Street, New York, NY 10021, USA.United States
- 通讯作者单位
- Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th Street, Office 21-268, New York, NY 10021, USA. Electronic address: thompsm2@mskcc.org.United States
- 文献类型
- 综述 · 美国 NIH 资助研究 · 非美国政府资助研究
- 期刊
- Hematology/oncology clinics of North America2025 Oct
- 原文标识
- PubMed 40675858 · DOI 10.1016/j.hoc.2025.05.008
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →